Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab

被引：76

作者：

Taniguchi, Yoshihiko ^{[1
]}

Tamiya, Akihiro ^{[1
]}

Isa, Syun-Ichi ^{[2
]}

Nakahama, Kenji ^{[1
]}

Okishio, Kyoichi ^{[2
]}

Shiroyama, Takayuki ^{[3
]}

Suzuki, Hidekazu ^{[3
]}

Inoue, Takako ^{[4
]}

Tamiya, Motohiro ^{[4
]}

Hirashima, Tomonori ^{[3
]}

Imamura, Fumio ^{[4
]}

Atagi, Shinji ^{[2
]}

机构：

[1] Natl Hosp Org Kinki Chuo Chest Med Ctr, Dept Internal Med, Sakai, Osaka, Japan

[2] Natl Hosp Org Kinki Chuo Chest Med Ctr, Dept Clin Res Ctr, Sakai, Osaka, Japan

[3] Osaka Habikino Med Ctr, Dept Thorac Oncol, Habikino, Japan

[4] Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan

来源：

ANTICANCER RESEARCH | 2017年 / 37卷 / 10期

关键词：

Non-small-cell lung cancer; immune checkpoint inhibitor; program death 1; nivolumab; prognosis; progression-free survival; SERUM LACTATE-DEHYDROGENASE; METASTATIC MELANOMA; ANTI-PD-1; ANTIBODY; ADVERSE EVENTS; PD-1; PATHWAY; DOCETAXEL; BLOCKADE; IMMUNOTHERAPY; CHEMOTHERAPY; OUTCOMES;

D O I：

10.21873/anticanres.12030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Nivolumab has shown promising effects in patients with non-small-cell lung cancer (NSCLC) as a second-or later-line treatment. This study aimed to identify patients who would not experience any benefit from nivolumab treatment. Materials and Methods: In this study, data for 201 patients treated with nivolumab during 17 December 2015 to 31 July 2016 at three respiratory medical centers in Japan were retrospectively reviewed. We collected clinical data at the time of nivolumab treatment commencement. We investigated the relationship between progression-free survival (PFS) and patient characteristics. Results: In both univariate and multivariate analysis, performance status (PS) score >= 2, steroid use at baseline and lactate dehydrogenase (LDH) level >240 IU/l were significantly associated with poor PFS (all p<0.05). Conclusion: PS score >= 2, steroid use at baseline and a high LDH level were predictive of poor PFS in patients with NSCLC treated with nivolumab. Careful monitoring is recommended for treating such patients with nivolumab (UMIN-ID: UMIN000025908).

引用

页码：5857 / 5862

页数：6

共 25 条

[1] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[2] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[3] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[4]

Danner BC, 2010, ANTICANCER RES, V30, P1347

[5] Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma [J].

Diem, S. ;

Kasenda, B. ;

Spain, L. ;

Martin-Liberal, J. ;

Marconcini, R. ;

Gore, M. ;

Larkin, J. .

BRITISH JOURNAL OF CANCER, 2016, 114 (03) :256-261

[6]

Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730

[7] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[8] Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens [J].

Fossella, FV ;

DeVore, R ;

Kerr, RN ;

Crawford, J ;

Natale, RR ;

Dunphy, F ;

Kalman, L ;

Miller, V ;

Lee, JS ;

Moore, M ;

Gandara, D ;

Karp, D ;

Vokes, E ;

Kris, M ;

Kim, Y ;

Gamza, F ;

Hammershaimb, L .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2354-2362

[9] The PD-1 pathway in tolerance and autoimmunity [J].

Francisco, Loise M. ;

Sage, Peter T. ;

Sharpe, Arlene H. .

IMMUNOLOGICAL REVIEWS, 2010, 236 :219-242

[10] Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation [J].

Freeman, GJ ;

Long, AJ ;

Iwai, Y ;

Bourque, K ;

Chernova, T ;

Nishimura, H ;

Fitz, LJ ;

Malenkovich, N ;

Okazaki, T ;

Byrne, MC ;

Horton, HF ;

Fouser, L ;

Carter, L ;

Ling, V ;

Bowman, MR ;

Carreno, BM ;

Collins, M ;

Wood, CR ;

Honjo, T .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (07) :1027-1034

← 1 2 3 →